Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma - Wikidata - awgldk - TriplyDB

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

http://www.wikidata.org/entity/Q36284584

about

Immunotherapy for head and neck cancer: latest developments and clinical potential CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas The Role of Immunotherapy in Multiple Myeloma Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy CAR T Cell Therapy: A Game Changer in Cancer Treatment Development of Novel Immunotherapies for Multiple Myeloma Exploiting IL-17-producing CD4+ and CD8+ T cells to improve cancer immunotherapy in the clinic Redirecting Specificity of T cells Using the Sleeping Beauty System to Express Chimeric Antigen Receptors by Mix-and-Matching of VL and VH Domains Targeting CD123+ Tumors The role of SLAMF7 in multiple myeloma: impact on therapy.Elutriated lymphocytes for manufacturing chimeric antigen receptor T cells.Autologous lymphapheresis for the production of chimeric antigen receptor T cells.Tumor-infiltrating lymphocytes are dynamically desensitized to antigen but are maintained by homeostatic cytokine.Differentiation stage of myeloma plasma cells: biological and clinical significance.Genome-Edited T Cell Therapies.Engineering cord blood to improve engraftment after cord blood transplant.Driving CAR T-cells forward The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies Occurrence and prognostic significance of cytogenetic evolution in patients with multiple myeloma.Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy Molecular Pathways: Breaking the Epithelial Cancer Barrier for Chimeric Antigen Receptor and T-cell Receptor Gene Therapy Myeloid cells in peripheral blood mononuclear cell concentrates inhibit the expansion of chimeric antigen receptor T cells.Persistence of long-lived plasma cells and humoral immunity in individuals responding to CD19-directed CAR T-cell therapy Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of hematologic malignancies: multiple myeloma, lymphoma, and acute leukemia.Immunotherapy of acute leukemia by chimeric antigen receptor-modified lymphocytes using an improved Sleeping Beauty transposon platform.Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.Carfilzomib boosted combination therapy for relapsed multiple myeloma Potent in vitro and in vivo effects of polyclonal anti-human-myeloma globulins.Membrane-Proximal Epitope Facilitates Efficient T Cell Synapse Formation by Anti-FcRH5/CD3 and Is a Requirement for Myeloma Cell Killing Immunostimulatory Effects of Melphalan and Usefulness in Adoptive Cell Therapy with Antitumor CD4+ T Cells.How do i participate in T-cell immunotherapy?Opportunities and challenges for the cellular immunotherapy sector: a global landscape of clinical trials.Fast Cars and No Brakes: Autologous Stem Cell Transplantation as a Platform for Novel Immunotherapies.Cancer Immunotherapy: Historical Perspective of a Clinical Revolution and Emerging Preclinical Animal Models.CAR T-cells merge into the fast lane of cancer care.Adoptive Cell Therapy in Multiple Myeloma.Novel Immunotherapies for Multiple Myeloma.Chimeric antigen receptor T cells for the treatment of cancer and the future of preclinical models for predicting their toxicities.Current and developing synthetic pharmacotherapy for treating relapsed/refractory multiple myeloma.Stem cell transplantation in multiple myeloma and other plasma cell disorders (report from an EBMT preceptorship meeting).

P2860

Q26745428-5223CB67-2EDA-45FD-B446-0DB0DD5DED3F Q26749139-4E716DF3-7DFA-43A5-B081-51FF7B3DC49F Q26771144-1584725E-CD6B-4166-91C8-B88C2D5307F8 Q26773309-E8CD8B77-80C5-4691-94D9-A1ECE807E927 Q26822769-4023D290-2779-4429-9B9C-6FB2F1BD8FF8 Q28066890-D27D3504-6A01-4357-9756-AB1DB2FA2E4E Q28075992-CB33F89C-FD26-4E5A-A02C-883011B21E37 Q28553650-C0A1294A-CD4B-4CD0-91D0-593470B9276E Q30249167-4D1A867E-8634-4146-BB1E-53827C8623EC Q30252944-3A7D7292-7C1F-42FE-B5E6-BBDC1571572E Q30253090-15AB8EC9-C5EB-4D6B-A87E-D3B322ADC8F6 Q30830664-BFB6A11E-FCD7-4D4F-BBEA-8ADB5E52B37C Q33712516-DF45DA3A-A7F7-4EBF-B97B-2F639323E8D3 Q33729598-99711753-1EB8-4772-8618-6C0DC03BBB0A Q33766995-23888FE8-52FB-46E4-BB94-B611C298D9CC Q34046505-76ADC92F-BC93-4A34-88DA-A52FB833BC6D Q36547199-85188C21-C75A-4FCC-8BB6-495EC25C8DAE Q36754816-9AB078D8-D1DE-4CC0-91AE-5416323ABD44 Q36830759-B05B06F6-2365-4A5B-8750-2616F5C3A03B Q36928580-C4179350-EE94-4660-9F08-A0D24FA3A458 Q36982805-555CE5FE-8D4D-45A6-9B5F-14B406A35252 Q37117624-D39A8C64-4AFF-49BF-B0DE-3D676504544A Q37217432-A3CAC4EE-F832-4308-946F-DE577E33ADCF Q37517482-03D69743-8E9A-47D2-A7BC-C4929D7BC481 Q37588329-16FB9EDD-EAF9-4C89-93CF-7BBB3A12A136 Q37609801-A30752D7-5DA6-4CB6-B2D8-40B9134BA27D Q37652953-5540967F-9770-43A7-A4D3-F9E4B2F7741B Q37687119-B9E362F8-BF12-4345-A7FE-150FD842454F Q37710498-D8CCF029-FBE5-4F3A-8376-F4F948D33C80 Q37722551-6B93A08D-FBF0-4A5E-A4EF-DE325C8A7997 Q38371637-13A18976-D499-48F5-AD00-3611FCDB73D5 Q38604100-E79D6A14-4A12-4F7D-9973-16B29C03160F Q38612233-31FCF632-0349-4BCD-8451-F36AC788131C Q38616707-BA6355A9-0DA5-4844-A501-31D98F223273 Q38635027-F89A4B91-2791-4134-BA2B-0F92D577F065 Q38635138-F9869D56-B099-471C-B843-3E842A6153BF Q38640444-D9FCFD55-FA71-4BB6-A998-BF6E57C59962 Q38666256-CB003D4B-7938-4BFF-A399-8DD91992540C Q38672091-E6CC43B2-5FA6-4BAA-9F0F-83BA3AF48088 Q38688055-9D92201D-1C9C-4BCD-8C1A-5CE07DEB9BEC

P2860

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

http://www.wikidata.org/entity/Q36284584

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

@ast

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

@en

type

label

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

@ast

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

@en

prefLabel

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

@ast

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

@en

P1433

Q36284584-35171743-BF34-4B16-8AD8-A31C07143F7F

P1476

Q36284584-694AB7EB-F560-4B5E-B4A7-7A064152D050

P2093

Q36284584-0768F471-0052-4F71-901C-C1F6ABD77BA3

Q36284584-440E4FCA-D5A3-4BAE-B421-356F40C4521E

Q36284584-49815577-1B8F-4B69-A2DF-107A3CF13858

Q36284584-4F98296A-DBCE-4233-A335-15F6D377B662

Q36284584-5457D729-AC4C-4C95-A0E3-408E097C4C08

Q36284584-5D13778F-25E7-4CB7-A843-2B343DB7C869

Q36284584-9840FE21-7F81-4B64-ADE3-8E05FE6C2667

Q36284584-A1355E22-FEF6-4DBA-ACFD-20B1E6798F6A

Q36284584-A8589B9E-950A-4A51-92DF-6FCBED4F4904

Q36284584-BF562A95-E056-44E2-8D22-7AF3E22108CE

P2860

Q36284584-1A9B6F59-42ED-4D68-99B9-9529E86D8199

Q36284584-2225EFE0-1A70-4DD8-B099-4F351A67C76E

Q36284584-330E837D-43B8-4274-8F16-FA39D2A341FF

Q36284584-33F8E9B7-AD3F-4EDD-A438-18AC2F334596

Q36284584-7FEDBFCC-F265-437B-9F92-32327499AD93

Q36284584-8035016A-24E3-4844-921E-9ED0BAF58D39

Q36284584-876EBD0D-D221-460F-ABA1-8A565BF8D81B

Q36284584-9577BDF3-32CF-4203-A891-18C1FA1A3CFE

Q36284584-98E9F704-6CA9-4650-8887-63CB89799CF6

Q36284584-9A61E8D4-F903-4215-85F7-5C4B838CCBDF

P304

Q36284584-F781D851-49E6-4338-BEE0-BC5E65B426FC

P31

Q36284584-E7030AA5-2BC8-40F2-B92B-7C27C87405C5

P356

Q36284584-E99765BC-9A59-4EF3-BE2E-07342D745F78

P407

Q36284584-DF709F0E-75EA-46D5-945C-B788A7028558

P433

Q36284584-DABA84B1-3CFF-4EBD-A7C2-8BC3460EC946

P478

Q36284584-75B184C8-7888-4AAB-B083-8404389289EE

P50

Q36284584-79CB3AF9-68B2-4659-8FBD-B3C057D6DF92

Q36284584-ACA173FD-02D1-471C-BDF3-EBD4D7FE200E

Q36284584-CCC5F8C5-8B4F-440B-90AA-451D541D1F1C

Q36284584-D429A452-D6FB-4909-A6E0-736A48742506

P577

Q36284584-03CE0D08-BCE6-4C9A-802E-380C64DAB3B4

P698

Q36284584-9180448E-EBCF-419E-8A46-75B4EEE2F192

P932

Q36284584-9D8C3891-DD52-4541-8356-5825A36DBF03

P356

P1433

The New England Journal of Medicine

P1476

Chimeric Antigen Receptor T Cells against CD19 for Multiple Myeloma

@en

P2093

Adam Bagg

http://www.w3.org/2001/XMLSchema#string

Brendan M Weiss

http://www.w3.org/2001/XMLSchema#string

Bruce L Levine

http://www.w3.org/2001/XMLSchema#string

Carl H June

http://www.w3.org/2001/XMLSchema#string

Dan T Vogl

http://www.w3.org/2001/XMLSchema#string

Edward A Stadtmauer

http://www.w3.org/2001/XMLSchema#string

J Joseph Melenhorst

http://www.w3.org/2001/XMLSchema#string

Karen Dengel

http://www.w3.org/2001/XMLSchema#string

Naseem D S Kerr

http://www.w3.org/2001/XMLSchema#string

Simon F Lacey

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Chimeric antigen receptor T cells for sustained remissions in leukemia

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

Rapid immune recovery and graft-versus-host disease-like engraftment syndrome following adoptive transfer of Costimulated autologous T cells.

B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas.

A proto-oncogene BCL6 is up-regulated in the bone marrow microenvironment in multiple myeloma cells.

Current concepts in the diagnosis and management of cytokine release syndrome.

International uniform response criteria for multiple myeloma.

Transfer of influenza vaccine-primed costimulated autologous T cells after stem cell transplantation for multiple myeloma leads to reconstitution of influenza immunity: results of a randomized clinical trial.

P304

1040-1047

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1504542

http://www.w3.org/2001/XMLSchema#string

P407

P433

11

http://www.w3.org/2001/XMLSchema#string

P478

373

http://www.w3.org/2001/XMLSchema#string

P50

Alfred L Garfall

P577

2015-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26352815

http://www.w3.org/2001/XMLSchema#string

P932

4646711

http://www.w3.org/2001/XMLSchema#string